1. Home
  2. Pharma & Healthcare
  3. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Status and Forecast 2021-2027

Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Status and Forecast 2021-2027

Publication Month: Sep 2021 | No. of Pages: 134 Published By: GRD Survey
Single User License: US $ 2980
Corporate User License: US $ 5960

This report provides a comprehensive analysis of current global Neuromyelitis Optica Spectrum Disorder (NMOSD) market based on segmented types and downstream applications. Major product development trends are discussed under major downstream segment scenario.This report also focuses on major driving factors and inhibitors that affect the market and competitive landscape. Global and regional leading players in the Neuromyelitis Optica Spectrum Disorder (NMOSD) industry are profiled in a detailed way, with sales data and market share info. This report also includes global and regional market size and forecast, drill-down to top 20 economies.

According to this survey, the global Neuromyelitis Optica Spectrum Disorder (NMOSD) market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million by 2027.

Covid-19 pandemic has impacted the supply and demand status for many industries along the supply chain. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Status and Forecast 2021-2027 report makes a brilliant attempt to unveil key opportunities available in the global Neuromyelitis Optica Spectrum Disorder (NMOSD) market under the covid-19 impact to help readers in achieving a better market position. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information.

The Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market has been exhibited in detail in the following chapters
Chapter 1 displays the basic product introduction and market overview.
Chapter 2 provides the competition landscape of global Neuromyelitis Optica Spectrum Disorder (NMOSD) industry.
Chapter 3 provides the market analysis by type and by region
Chapter 4 provides the market analysis by application and by region
Chapter 5-10 presents regional and country market size and forecast, under the context of market drivers and inhibitors analysis.
Chapter 11 analyses the supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis.
Chapter 12 provides the market forecast by type and by application
Chapter 13 provides the market forecast by region
Chapter 14 profies global leading players with their revenue, market share, profit margin, major product portfolio and SWOT analysis.
Chapter 15 conclusions

Segmented by Type
Intravenous
Oral
Subcutaneous
Others

Segmented by Application
Hospital
Clinic
Others

Segmented by Country
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Spain
Asia Pacific
China
Japan
Korea
Southeast Asia
India
Australasia
Central & South America
Brazil
Argentina
Colombia
Middle East & Africa
Iran
Israel
Turkey
South Africa
Saudi Arabia

Key manufacturers included in this survey
TG Therapeutics
RemeGen
Opexa Therapeutics
Nihon Pharmaceutical
Lundbeck
Harbour BioMed
F. Hoffmann-La Roche Ltd
Cour Pharmaceutical
Boston Pharmaceuticals
Bio-Thera Solutions
Bionure
Alexion Pharmaceuticals


Table of Contents

1 Product Introduction and Overview
1.1 Product Definition
1.2 Product Specification
1.3 Global Market Overview
1.3.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Status and Forecast (2016-2027)
1.3.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value CAGR by Region
1.4 Market Drivers, Inhibitors
1.4.1 Market Drivers
1.4.2 Market Inhibitors
1.4.3 COVID-19 Impact Analysis
2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Supply by Company
2.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value by Company
2.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Area of Main Manufacturers
2.3 Trend of Concentration Rate
3 Global and Regional Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Status by Type
3.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Type Introduction
3.1.1 Intravenous
3.1.2 Oral
3.1.3 Subcutaneous
3.1.4 Others
3.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market by Type
3.3 North America: by Type
3.4 Europe: by Type
3.5 Asia Pacific: by Type
3.6 Central & South America: by Type
3.7 Middle East & Africa: by Type
4 Global and Regional Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Status by Application
4.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Segment by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Others
4.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market by Application
4.3 North America: by Application
4.4 Europe: by Application
4.5 Asia Pacific: by Application
4.6 Central & South America: by Application
4.7 Middle East & Africa: by Application
5 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Status by Region
5.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market by Region
5.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Status
5.3 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Status
5.4 Asia Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Status
5.5 Central & South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Status
5.6 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Status
6 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Status
6.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market by Country
6.2 United States
6.3 Canada
6.4 Mexico
7 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Status
7.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market by Country
7.2 Germany
7.3 France
7.4 UK
7.5 Italy
7.6 Russia
7.7 Spain
8 Asia Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Status
8.1 Asia Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market by Country
8.2 China
8.3 Japan
8.4 Korea
8.5 Southeast Asia
8.6 India
8.7 Australasia
9 Central & South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Status
9.1 Central & South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market by Country
9.2 Brazil
9.3 Argentina
9.4 Colombia
10 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Status
10.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market by Country
10.2 Iran
10.3 Israel
10.4 Turkey
10.5 South Africa
10.8 Saudi Arabia
11 Major Downstream Customers Analysis
11.1 Customer One Analysis
11.2 Customer Two Analysis
11.3 Customer Three Analysis
11.4 Customer Four Analysis
12 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Forecast by Type and by Application
12.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value Forecast (2022-2027)
12.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecast by Type
12.3 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecast by Application
13 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Forecast by Region/Country
13.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Forecast by Region (2022-2027)
13.2 North America Market Forecast
13.3 Europe Market Forecast
13.4 Asia Pacific Market Forecast
13.5 Central & South America Market Forecast
13.6 Middle East & Africa Market Forecast
14 Key Participants Company Information
14.1 TG Therapeutics
14.1.1 Company Information
14.1.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Introduction
14.1.3 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value, Gross Margin and Global Share (2019-2021)
14.1.4 SWOT Analysis
14.2 RemeGen
14.2.1 Company Information
14.2.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Introduction
14.2.3 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value, Gross Margin and Global Share (2019-2021)
14.2.4 SWOT Analysis
14.3 Opexa Therapeutics
14.3.1 Company Information
14.3.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Introduction
14.3.3 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value, Gross Margin and Global Share (2019-2021)
14.3.4 SWOT Analysis
14.4 Nihon Pharmaceutical
14.4.1 Company Information
14.4.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Introduction
14.4.3 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value, Gross Margin and Global Share (2019-2021)
14.4.4 SWOT Analysis
14.5 Lundbeck
14.5.1 Company Information
14.5.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Introduction
14.5.3 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value, Gross Margin and Global Share (2019-2021)
14.5.4 SWOT Analysis
14.6 Harbour BioMed
14.6.1 Company Information
14.6.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Introduction
14.6.3 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value, Gross Margin and Global Share (2019-2021)
14.6.4 SWOT Analysis
14.7 F. Hoffmann-La Roche Ltd
14.7.1 Company Information
14.7.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Introduction
14.7.3 F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value, Gross Margin and Global Share (2019-2021)
14.7.4 SWOT Analysis
14.8 Cour Pharmaceutical
14.8.1 Company Information
14.8.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Introduction
14.8.3 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value, Gross Margin and Global Share (2019-2021)
14.8.4 SWOT Analysis
14.9 Boston Pharmaceuticals
14.9.1 Company Information
14.9.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Introduction
14.9.3 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value, Gross Margin and Global Share (2019-2021)
14.9.4 SWOT Analysis
14.10 Bio-Thera Solutions
14.10.1 Company Information
14.10.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Introduction
14.10.3 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value, Gross Margin and Global Share (2019-2021)
14.10.4 SWOT Analysis
14.11 Bionure
14.12 Alexion Pharmaceuticals
15 Conclusion
16 Methodology

Tables and Figures

List of Tables

Table Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value (Million USD) and CAGR by Region (2016-2027)
Table Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value (Million USD) by Company (2019-2021)
Table Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value Market Share by Company (2019-2021)
Table Main Manufacturers Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Area
Table Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Concentration (Top 3, Top 5) (2019-2021)
Table Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value (Million USD) by Type (2016-2021)
Table Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Sals Value Market Share by Type (2016-2021)
Table North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value (Million USD) by Type (2016-2021)
Table North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value Market Share by Type (2016-2021)
Table Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value (Million USD) by Type (2016-2021)
Table Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value Market Share by Type (2016-2021)
Table Asia Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value (Million USD) by Type (2016-2021)
Table Asia Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value Market Share by Type (2016-2021)
Table Central & South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value (Million USD) by Type (2016-2021)
Table Central & South America Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value Market Share by Type (2016-2021)
Table Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value (Million USD) by Type (2016-2021)
Table Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value Market Share by Type (2016-2021)
Table Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value (Million USD) by Application (2016-2021)
Table Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Value Market Share by Application (2016-2021)
Table North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value (Million USD) by Application (2016-2021)
Table North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value Market Share by Application (2016-2021)
Table Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value (Million USD) by Application (2016-2021)
Table Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value Market Share by Application (2016-2021)
Table Asia Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value (Million USD) by Application (2016-2021)
Table Asia Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value Market Share by Application (2016-2021)
Table Central & South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value (Million USD) by Application (2016-2021)
Table Central & South America Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value Market Share by Application (2016-2021)
Table Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value (Million USD) by Application (2016-2021)
Table Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value Market Share by Application (2016-2021)
Table Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value (Million USD) by Region (2016-2021)
Table Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Value Market Share by Region (2016-2021)
Table North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value (Million USD) by Country (2016-2021)
Table North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Value Market Share by Country (2016-2021)
Table Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value (Million USD) by Country (2016-2021)
Table Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Value Market Share by Country (2016-2021)
Table Asia Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value (Million USD) by Country (2016-2021)
Table Asia Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Value Market Share by Country (2016-2021)
Table Central & South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value (Million USD) by Country (2016-2021)
Table Central & South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Value Market Share by Country (2016-2021)
Table Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value (Million USD) by Country (2016-2021)
Table Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Value Market Share by Country (2016-2021)
Table Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Value (Million USD) Forecast by Type (2022-2027)
Table Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Value Market Share Forecast by Type (2022-2027)
Table Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Value (Million USD) Forecast by Application (2022-2027)
Table Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Value Market Share Forecast by Application (2022-2027)
Table Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Value (Million USD) Forecast by Region (2022-2027)
Table Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Value Market Share Forecast by Region (2022-2027)
Table TG Therapeutics Company Information
Table TG Therapeutics Product Introduction
Table TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value, Gross Margin and Global Share (2019-2021)
Table RemeGen Company Information
Table RemeGen Product Introduction
Table RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value, Gross Margin and Global Share (2019-2021)
Table Opexa Therapeutics Company Information
Table Opexa Therapeutics Product Introduction
Table Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value, Gross Margin and Global Share (2019-2021)
Table Nihon Pharmaceutical Company Information
Table Nihon Pharmaceutical Product Introduction
Table Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value, Gross Margin and Global Share (2019-2021)
Table Lundbeck Company Information
Table Lundbeck Product Introduction
Table Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value, Gross Margin and Global Share (2019-2021)
Table Harbour BioMed Company Information
Table Harbour BioMed Product Introduction
Table Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value, Gross Margin and Global Share (2019-2021)
Table F. Hoffmann-La Roche Ltd Company Information
Table F. Hoffmann-La Roche Ltd Product Introduction
Table F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value, Gross Margin and Global Share (2019-2021)
Table Cour Pharmaceutical Company Information
Table Cour Pharmaceutical Product Introduction
Table Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value, Gross Margin and Global Share (2019-2021)
Table Boston Pharmaceuticals Company Information
Table Boston Pharmaceuticals Product Introduction
Table Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value, Gross Margin and Global Share (2019-2021)
Table Bio-Thera Solutions Company Information
Table Bio-Thera Solutions Product Introduction
Table Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales Value, Gross Margin and Global Share (2019-2021)


Reason to Buy

  • Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The segment that is expected to dominate the Pharma & Healthcare Market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets